| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing informatics challenges in Translational Research with workflow technology
|
Beaulah, Simon A.
|
|
2008
|
|
17-18 |
p. 771-777
7 p.
|
artikel
|
| 2 |
Agmatine: clinical applications after 100 years in translation
|
Piletz, John E.
|
|
2013
|
|
17-18 |
p. 880-893
14 p.
|
artikel
|
| 3 |
A new anti-inflammatory spirolactone derivative from Dendrobium chrysanthum
|
Barlocco, Daniela
|
|
2006
|
|
17-18 |
p. 860-
1 p.
|
artikel
|
| 4 |
Applying computational modeling to drug discovery and development
|
Kumar, Neil
|
|
2006
|
|
17-18 |
p. 806-811
6 p.
|
artikel
|
| 5 |
Approaches to seizure risk assessment in preclinical drug discovery
|
Easter, Alison
|
|
2009
|
|
17-18 |
p. 876-884
9 p.
|
artikel
|
| 6 |
A quality alert and call for improved curation of public chemistry databases
|
Williams, Antony J.
|
|
2011
|
|
17-18 |
p. 747-750
4 p.
|
artikel
|
| 7 |
A remote-controlled adaptive medchem lab: an innovative approach to enable drug discovery in the 21st Century
|
Godfrey, Alexander G.
|
|
2013
|
|
17-18 |
p. 795-802
8 p.
|
artikel
|
| 8 |
Avoiding physicochemical artefacts in early ADME–Tox experiments
|
DeWitte, Robert S.
|
|
2006
|
|
17-18 |
p. 855-859
5 p.
|
artikel
|
| 9 |
Better compounds faster: the development and exploitation of a desktop predictive chemistry toolkit
|
Cumming, John G.
|
|
2012
|
|
17-18 |
p. 923-927
5 p.
|
artikel
|
| 10 |
Biotech acquisitions by big pharma: why and what is next
|
Malik, Nafees N.
|
|
2009
|
|
17-18 |
p. 818-821
4 p.
|
artikel
|
| 11 |
Blood–brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling brain drug delivery
|
Calabria, Anthony R.
|
|
2006
|
|
17-18 |
p. 792-799
8 p.
|
artikel
|
| 12 |
Cancer therapy via modulation of micro RNA levels: a promising future
|
Kota, Satya K.
|
|
2010
|
|
17-18 |
p. 733-740
8 p.
|
artikel
|
| 13 |
Carbon nanotube exploration in cancer cell lines
|
Kesharwani, Prashant
|
|
2012
|
|
17-18 |
p. 1023-1030
8 p.
|
artikel
|
| 14 |
Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem
|
Force, Thomas
|
|
2008
|
|
17-18 |
p. 778-784
7 p.
|
artikel
|
| 15 |
Chondrocyte genomics: implications for disease modification in osteoarthritis
|
Marshall, K. Wayne
|
|
2006
|
|
17-18 |
p. 825-832
8 p.
|
artikel
|
| 16 |
Clinical and biological data integration for biomarker discovery
|
Sorani, Marco D.
|
|
2010
|
|
17-18 |
p. 741-748
8 p.
|
artikel
|
| 17 |
Combinatorial approaches to combating multidrug resistance
|
Edwards, Paul
|
|
2007
|
|
17-18 |
p. 786-787
2 p.
|
artikel
|
| 18 |
Contents
|
|
|
2010
|
|
17-18 |
p. i-
1 p.
|
artikel
|
| 19 |
Contents
|
|
|
2008
|
|
17-18 |
p. i-
1 p.
|
artikel
|
| 20 |
Contents
|
|
|
2007
|
|
17-18 |
p. iii-
1 p.
|
artikel
|
| 21 |
Contents
|
|
|
2008
|
|
17-18 |
p. iii-
1 p.
|
artikel
|
| 22 |
Contents
|
|
|
2010
|
|
17-18 |
p. iii-
1 p.
|
artikel
|
| 23 |
Contents
|
|
|
2011
|
|
17-18 |
p. i-
1 p.
|
artikel
|
| 24 |
Contents
|
|
|
2011
|
|
17-18 |
p. iii-
1 p.
|
artikel
|
| 25 |
Contents
|
|
|
2013
|
|
17-18 |
p. iii-
1 p.
|
artikel
|
| 26 |
Contents
|
|
|
2013
|
|
17-18 |
p. i-
1 p.
|
artikel
|
| 27 |
Contents
|
|
|
2012
|
|
17-18 |
p. i-
1 p.
|
artikel
|
| 28 |
Contents
|
|
|
2012
|
|
17-18 |
p. iii-
1 p.
|
artikel
|
| 29 |
Contents page 2
|
|
|
2009
|
|
17-18 |
p. iii-
1 p.
|
artikel
|
| 30 |
Contents page 1
|
|
|
2009
|
|
17-18 |
p. i-
1 p.
|
artikel
|
| 31 |
Corrigendum to “Targeting mammalian target of rapamycin (mTOR) for health and diseases”
|
|
|
2008
|
|
17-18 |
p. 824-
1 p.
|
artikel
|
| 32 |
Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study
|
Kooloos, Wouter M.
|
|
2009
|
|
17-18 |
p. 837-844
8 p.
|
artikel
|
| 33 |
Cytomics as a new potential for drug discovery
|
Valet, Günter
|
|
2006
|
|
17-18 |
p. 785-791
7 p.
|
artikel
|
| 34 |
Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain
|
Borsook, David
|
|
2012
|
|
17-18 |
p. 964-973
10 p.
|
artikel
|
| 35 |
Designing drugs for the treatment of female sexual dysfunction
|
Brown, Alan D.
|
|
2007
|
|
17-18 |
p. 757-766
10 p.
|
artikel
|
| 36 |
Diary
|
|
|
2006
|
|
17-18 |
p. 861-
1 p.
|
artikel
|
| 37 |
DIARY
|
|
|
2007
|
|
17-18 |
p. 788-
1 p.
|
artikel
|
| 38 |
Discovery of anticancer drugs from antimalarial natural products: a MEDLINE literature review
|
Duffy, Robert
|
|
2012
|
|
17-18 |
p. 942-953
12 p.
|
artikel
|
| 39 |
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art
|
Italia, Jagdish L.
|
|
2006
|
|
17-18 |
p. 846-854
9 p.
|
artikel
|
| 40 |
Dissecting kinase signaling pathways
|
Boyle, Scott N.
|
|
2007
|
|
17-18 |
p. 717-724
8 p.
|
artikel
|
| 41 |
Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity
|
Fryburg, David A.
|
|
2010
|
|
17-18 |
p. 766-772
7 p.
|
artikel
|
| 42 |
Drug discovery from uncultivable microorganisms
|
Singh, Brajesh K.
|
|
2010
|
|
17-18 |
p. 792-799
8 p.
|
artikel
|
| 43 |
Drug discovery in the next decade: innovation needed ASAP
|
Bennani, Youssef L.
|
|
2011
|
|
17-18 |
p. 779-792
14 p.
|
artikel
|
| 44 |
Drug name recognition and classification in biomedical texts
|
Segura-Bedmar, Isabel
|
|
2008
|
|
17-18 |
p. 816-823
8 p.
|
artikel
|
| 45 |
Drug profiling: knowing where it hits
|
Merino, Alejandro
|
|
2010
|
|
17-18 |
p. 749-756
8 p.
|
artikel
|
| 46 |
Editorial Board
|
|
|
2007
|
|
17-18 |
p. v-
1 p.
|
artikel
|
| 47 |
Emerging treatments for thrombocytopenia: Increasing platelet production
|
Peeters, Karen
|
|
2008
|
|
17-18 |
p. 798-806
9 p.
|
artikel
|
| 48 |
Estonia: small country, big ambitions
|
O’Neill, Michael
|
|
2007
|
|
17-18 |
p. 683-687
5 p.
|
artikel
|
| 49 |
Exploiting the enhanced permeability and retention effect for tumor targeting
|
Iyer, Arun K.
|
|
2006
|
|
17-18 |
p. 812-818
7 p.
|
artikel
|
| 50 |
Ex vivo fucosylation to improve the engraftment capability and therapeutic potential of human cord blood stem cells
|
Taupin, Philippe
|
|
2010
|
|
17-18 |
p. 698-699
2 p.
|
artikel
|
| 51 |
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
|
Adorini, Luciano
|
|
2012
|
|
17-18 |
p. 988-997
10 p.
|
artikel
|
| 52 |
Function and regulation of large conductance Ca2+-activated K+ channel in vascular smooth muscle cells
|
Hu, Xiang-Qun
|
|
2012
|
|
17-18 |
p. 974-987
14 p.
|
artikel
|
| 53 |
Future directions for peptide therapeutics development
|
Kaspar, Allan A.
|
|
2013
|
|
17-18 |
p. 807-817
11 p.
|
artikel
|
| 54 |
Getting on the critical path: better evaluation tools for drug discovery and development
|
Hrusovsky, Kevin
|
|
2006
|
|
17-18 |
p. 773-774
2 p.
|
artikel
|
| 55 |
Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity
|
Young, Robert J.
|
|
2011
|
|
17-18 |
p. 822-830
9 p.
|
artikel
|
| 56 |
Glucocorticoid-resistant asthma and novel anti-inflammatory drugs
|
Keenan, Christine R.
|
|
2012
|
|
17-18 |
p. 1031-1038
8 p.
|
artikel
|
| 57 |
Going to the dark side: success factors for companies leveraging senior academic talent
|
Yun, Joanne W.
|
|
2009
|
|
17-18 |
p. 815-817
3 p.
|
artikel
|
| 58 |
How well do medicinal chemists learn from experience?
|
Cheshire, David R.
|
|
2011
|
|
17-18 |
p. 817-821
5 p.
|
artikel
|
| 59 |
Human protein–protein interaction networks and the value for drug discovery
|
Ruffner, Heinz
|
|
2007
|
|
17-18 |
p. 709-716
8 p.
|
artikel
|
| 60 |
Insights into the novel three ‘D's of epilepsy treatment: drugs, delivery systems and devices
|
Pathan, Shadab A.
|
|
2010
|
|
17-18 |
p. 717-732
16 p.
|
artikel
|
| 61 |
In silico SNP analysis and bioinformatics tools: a review of the state of the art to aid drug discovery
|
Mah, James T.L.
|
|
2011
|
|
17-18 |
p. 800-809
10 p.
|
artikel
|
| 62 |
In vivo assessment of mitochondrial toxicity
|
Hamilton, Bradley F.
|
|
2008
|
|
17-18 |
p. 785-790
6 p.
|
artikel
|
| 63 |
Is informed consent necessary for randomized Phase IV ‘observational’ drug studies?
|
Bernabe, Rosemarie D.C.
|
|
2011
|
|
17-18 |
p. 751-754
4 p.
|
artikel
|
| 64 |
Label-free whole-cell assays: expanding the scope of GPCR screening
|
Scott, Clay W
|
|
2010
|
|
17-18 |
p. 704-716
13 p.
|
artikel
|
| 65 |
Male pattern baldness: current treatments, future prospects
|
Ellis, Justine A.
|
|
2008
|
|
17-18 |
p. 791-797
7 p.
|
artikel
|
| 66 |
Matrix metalloproteinases as drug targets in ischemia/reperfusion injury
|
Dejonckheere, Eline
|
|
2011
|
|
17-18 |
p. 762-778
17 p.
|
artikel
|
| 67 |
Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab
|
Ebbers, Hans C.
|
|
2013
|
|
17-18 |
p. 872-879
8 p.
|
artikel
|
| 68 |
Medicines discovery in the 21st century: the case for a stakeholder corporation
|
Dixon, John
|
|
2010
|
|
17-18 |
p. 700-703
4 p.
|
artikel
|
| 69 |
Metrics and the effective computational scientist: process, quality and communication
|
Baldwin, Eric T.
|
|
2012
|
|
17-18 |
p. 935-941
7 p.
|
artikel
|
| 70 |
Modern agrochemical research: a missed opportunity for drug discovery?
|
Delaney, John
|
|
2006
|
|
17-18 |
p. 839-845
7 p.
|
artikel
|
| 71 |
Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)
|
Ahmed, Mohamed H.
|
|
2007
|
|
17-18 |
p. 740-747
8 p.
|
artikel
|
| 72 |
Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
|
Parhi, Priyambada
|
|
2012
|
|
17-18 |
p. 1044-1052
9 p.
|
artikel
|
| 73 |
Neurotrophic estrogens: essential profile and endpoints for drug discovery☆
|
Patchev, Vladimir K.
|
|
2008
|
|
17-18 |
p. 734-747
14 p.
|
artikel
|
| 74 |
α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?
|
Paleari, Laura
|
|
2009
|
|
17-18 |
p. 822-836
15 p.
|
artikel
|
| 75 |
Non-viral gene therapy for spinal cord regeneration
|
Yao, Li
|
|
2012
|
|
17-18 |
p. 998-1005
8 p.
|
artikel
|
| 76 |
Novel advances in cytochrome P450 research
|
Singh, Deepika
|
|
2011
|
|
17-18 |
p. 793-799
7 p.
|
artikel
|
| 77 |
on-course® portal: a tool for in-service training and career development for biomedical scientists
|
Payton, Antony
|
|
2013
|
|
17-18 |
p. 803-806
4 p.
|
artikel
|
| 78 |
‘OnePoint’ – combining OneNote and SharePoint to facilitate knowledge transfer
|
Barber, Christopher G.
|
|
2009
|
|
17-18 |
p. 845-850
6 p.
|
artikel
|
| 79 |
Open-source science to enable drug discovery
|
Edwards, Aled
|
|
2008
|
|
17-18 |
p. 731-733
3 p.
|
artikel
|
| 80 |
Orally bioavailable proteasome inhibitors: preclinical development of PR-047
|
Peese, Kevin
|
|
2009
|
|
17-18 |
p. 905-906
2 p.
|
artikel
|
| 81 |
Parthenolide: from plant shoots to cancer roots
|
Ghantous, Akram
|
|
2013
|
|
17-18 |
p. 894-905
12 p.
|
artikel
|
| 82 |
PET tracers for 5-HT1A receptors and uses thereof
|
Kumar, J.S. Dileep
|
|
2007
|
|
17-18 |
p. 748-756
9 p.
|
artikel
|
| 83 |
Pharmaceutical agents from filamentous marine cyanobacteria
|
Tan, Lik Tong
|
|
2013
|
|
17-18 |
p. 863-871
9 p.
|
artikel
|
| 84 |
Post-translational modifications of protein biopharmaceuticals
|
Walsh, Gary
|
|
2010
|
|
17-18 |
p. 773-780
8 p.
|
artikel
|
| 85 |
Progress in the discovery and development of glutamate carboxypeptidase II inhibitors
|
Tsukamoto, Takashi
|
|
2007
|
|
17-18 |
p. 767-776
10 p.
|
artikel
|
| 86 |
Rapid retrieval of protein structures from databases
|
Aung, Zeyar
|
|
2007
|
|
17-18 |
p. 732-739
8 p.
|
artikel
|
| 87 |
R&D technology investments: misguided and expensive or a better way to discover medicines?
|
Schmid, Esther F.
|
|
2006
|
|
17-18 |
p. 775-784
10 p.
|
artikel
|
| 88 |
Redox-active nuisance screening compounds and their classification
|
Baell, Jonathan B.
|
|
2011
|
|
17-18 |
p. 840-841
2 p.
|
artikel
|
| 89 |
Resveratrol and derivatives for the prevention and treatment of cancer
|
Fulda, Simone
|
|
2010
|
|
17-18 |
p. 757-765
9 p.
|
artikel
|
| 90 |
Risk-based strategy for the assessment of pharmacokinetic drug–drug interactions for therapeutic monoclonal antibodies
|
Zhou, Honghui
|
|
2009
|
|
17-18 |
p. 891-898
8 p.
|
artikel
|
| 91 |
Role of Sirtuin 1 in metabolic regulation
|
Silva, Jose P.
|
|
2010
|
|
17-18 |
p. 781-791
11 p.
|
artikel
|
| 92 |
Scientific competency questions as the basis for semantically enriched open pharmacological space development
|
Azzaoui, Kamal
|
|
2013
|
|
17-18 |
p. 843-852
10 p.
|
artikel
|
| 93 |
siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs
|
Hajeri, Praveensingh B.
|
|
2009
|
|
17-18 |
p. 851-858
8 p.
|
artikel
|
| 94 |
siRNAs: their potential as therapeutic agents – Part II. Methods of delivery
|
Singh, Sunit Kumar
|
|
2009
|
|
17-18 |
p. 859-865
7 p.
|
artikel
|
| 95 |
Structure-based drug design to augment hit discovery
|
Kalyaanamoorthy, Subha
|
|
2011
|
|
17-18 |
p. 831-839
9 p.
|
artikel
|
| 96 |
Synthetic drugs with anti-ageing effects
|
Kapoor, Vijay K.
|
|
2009
|
|
17-18 |
p. 899-904
6 p.
|
artikel
|
| 97 |
Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine
|
Eckelman, William C.
|
|
2008
|
|
17-18 |
p. 748-759
12 p.
|
artikel
|
| 98 |
Targeted library design for the generation of actives against biological targets
|
Edwards, Paul
|
|
2008
|
|
17-18 |
p. 827-828
2 p.
|
artikel
|
| 99 |
Targeted therapy of cancer using diphtheria toxin-derived immunotoxins
|
Potala, Sirisha
|
|
2008
|
|
17-18 |
p. 807-815
9 p.
|
artikel
|
| 100 |
Targeting mitochondrial apoptosis by betulinic acid in human cancers
|
Fulda, Simone
|
|
2009
|
|
17-18 |
p. 885-890
6 p.
|
artikel
|
| 101 |
The application of human embryonic stem cell technologies to drug discovery
|
Sartipy, Peter
|
|
2007
|
|
17-18 |
p. 688-699
12 p.
|
artikel
|
| 102 |
The array CGH and its clinical applications
|
Shinawi, Marwan
|
|
2008
|
|
17-18 |
p. 760-770
11 p.
|
artikel
|
| 103 |
The challenge of developing robust drugs to overcome resistance
|
Anderson, Amy C.
|
|
2011
|
|
17-18 |
p. 755-761
7 p.
|
artikel
|
| 104 |
The complexity of the GABAA receptor shapes unique pharmacological profiles
|
D’Hulst, Charlotte
|
|
2009
|
|
17-18 |
p. 866-875
10 p.
|
artikel
|
| 105 |
The development of molecular clamps as drugs
|
Weiss, Stephanie T.
|
|
2006
|
|
17-18 |
p. 819-824
6 p.
|
artikel
|
| 106 |
The future of antibodies as cancer drugs
|
Reichert, Janice M.
|
|
2012
|
|
17-18 |
p. 954-963
10 p.
|
artikel
|
| 107 |
The major gut symbiont reduces its genome when it lives in vitro
|
Demidov, Vadim V.
|
|
2008
|
|
17-18 |
p. 825-826
2 p.
|
artikel
|
| 108 |
The ongoing evolution of proteomics in malignancy
|
Dhamoon, Amit S.
|
|
2007
|
|
17-18 |
p. 700-708
9 p.
|
artikel
|
| 109 |
Theranostic applications of nanoparticles in cancer
|
Ahmed, Naveed
|
|
2012
|
|
17-18 |
p. 928-934
7 p.
|
artikel
|
| 110 |
Therapeutic potential of neuregulin-1 in cardiovascular disease
|
Mendes-Ferreira, Pedro
|
|
2013
|
|
17-18 |
p. 836-842
7 p.
|
artikel
|
| 111 |
The role of quantum mechanics in structure-based drug design
|
Raha, Kaushik
|
|
2007
|
|
17-18 |
p. 725-731
7 p.
|
artikel
|
| 112 |
The significance of mitochondrial toxicity testing in drug development
|
Dykens, James A.
|
|
2007
|
|
17-18 |
p. 777-785
9 p.
|
artikel
|
| 113 |
The structure of secretin family GPCR peptide ligands: implications for receptor pharmacology and drug development
|
Watkins, Harriet A.
|
|
2012
|
|
17-18 |
p. 1006-1014
9 p.
|
artikel
|
| 114 |
The virtual laboratory approach to pharmacokinetics: design principles and concepts
|
Huisinga, Wilhelm
|
|
2006
|
|
17-18 |
p. 800-805
6 p.
|
artikel
|
| 115 |
The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives
|
Bueters, Tjerk
|
|
2013
|
|
17-18 |
p. 853-862
10 p.
|
artikel
|
| 116 |
The virtuous technology cycle concept and its application in next-generation sequencing
|
Pluess-Li, Ying
|
|
2012
|
|
17-18 |
p. 1015-1022
8 p.
|
artikel
|
| 117 |
Translational research in the pharmaceutical industry: from bench to bedside
|
O’Connell, Damian
|
|
2006
|
|
17-18 |
p. 833-838
6 p.
|
artikel
|
| 118 |
Treatment strategies for vasculitis that affects the nervous system
|
Broussalis, Erasmia
|
|
2013
|
|
17-18 |
p. 818-835
18 p.
|
artikel
|
| 119 |
Truncated HER2: implications for HER2-targeted therapeutics
|
Zagozdzon, Radoslaw
|
|
2011
|
|
17-18 |
p. 810-816
7 p.
|
artikel
|
| 120 |
Viral targets of acylguanidines
|
Gazina, Elena V.
|
|
2012
|
|
17-18 |
p. 1039-1043
5 p.
|
artikel
|
| 121 |
Virtual drug discovery with the rise of Chinese CROs
|
Zhang, Ming-Qiang
|
|
2010
|
|
17-18 |
p. 693-697
5 p.
|
artikel
|
Tijdschrift beschrijving